Featured conditions Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Featured conditions
(for at least one location)
Rochester, MN
Describes the nature of a clinical study. Types include:
Panorama® is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Panorama analyzes SNPs to distinguish maternal from fetal (placental) DNA, targeting 13,932 SNPs covering chromosomes 21, 18, 13, X and Y, to determine chromosomal abnormalities and fetal sex. Panorama is used in twin pregnancies to screen for a variety of abnormalities, including trisomies 21, 18 and 13, monosomy X zygosity and fetal sex for each twin.
The primary objectives of this study are to use the Panorama® testing to: 1) Develop a new algorithm and methodology that will distinguish between the non-viable or demised twin and the living twin in dizygotic twins with a single living twin.. 2) Assess the accuracy of the new algorithm to determine which of the signals in the Panorama samples correspond to the living twin versus the non-viable or demised twin. .
Study statuses change often. Please contact us for help.
Open for enrollment
The purpose of this study is:
Infertility Cohort - To determine if maternal blood concentrations of Gal-9, IL-4, and VEGF-A, -C, -D at the time of embryo transfer in patients undergoing in vitro fertilization are predictive of the cycle outcome: live birth or no live birth
Spontaneous Conception Cohort - To determine if maternal blood concentrations of Gal-9, IL-4, and VEGF-A, -C, -D early in the first trimester of gestation are predictive of miscarriage or live birth.